UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

Kirby McInerney LLP issued a reminder that investors who suffered losses on Unicycive Therapeutics (NASDAQ: UNCY) have until November 2, 2026 to seek appointment as lead plaintiff in a pending securities fraud class action. The suit covers shareholders who purchased UNCY securities between December 29, 2025 and June 29, 2026, and alleges the company misled investors about its third-party manufacturing vendor's compliance with FDA current good manufacturing practices, putting approval of oxylanthanum carbonate (OLC), a kidney disease therapy, at risk of delay.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.